Agilent and Oxford Gene Technology expand partnership
Agilent Technologies and Oxford Gene Technology have announced that they have expanded an already existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays
Agilent Technologies and Oxford Gene Technology have announced that they have expanded an already existing partnership into an exclusive agreement for Agilent to provide OGT with oligonucleotide microarrays.
Chief executive of OGT, Mike Evans, said: “We are delighted to broaden our supply partnership with Agilent to include the industry-leading SureSelect platform for our recently launched Genefficiency next-generation sequencing service. We are also pleased to extend our OEM supply agreement for oligonucleotide microarrays, building on the success of our comprehensive CytoSure product range for cytogenetics.”
Robert Shueren, vice president and general manager of Agilent’s genomics business, said: “Agilent and OGT have a very close working relationship and we are excited to expand our collaboration to the SureSelect platform under our Certified Services Provider program. OGT’s bioinformatics capabilities add significant value to customers targeting specific areas of the genome with our SureSelect product line.”
The Agilent SureSelect Target Enrichment System is an in-solution hybridization capture technology which streamlines next-generation sequencing by enabling researchers to sequence only genomic regions of interest. It has enabled researchers to identify mutations associated with 50 Mendelian diseases, 10 different types of cancer and other ailments such as schizophrenia and Parkinson’s disease.
The SureSelect platform offers the most comprehensive offering of catalogue and custom capture kits, including the SureSelect Target Enrichment kit, gDNA prep kit and library prep kit, on all major sequencing platforms.
The SureSelect platform has led to 125 peer-reviewed discovery publications, the greatest number to date.
For more information, visit www.agilent.comThis story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
